Consequently, the administration of a COX-2 selective inhibiting agent and an alkylating-type antineoplastic agent, in combination with an agent, or agents, that inhibits or suppresses oncogenes is contemplated to prevent or treat cancers in which oncogenes are overexpressed. [1214] Accordingly, there is a need for a method of treating or preventing a cancer in a patient that overexpresses COX-2 o